Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs

World Health Organization - Technical Report Series

Volumn , Issue 941, 2007, Pages 83-132

  Bourhy, H ^a   Bruckner, L ^b   Correa De Moura, W ^c   Ferguson, Morag ^d   Grachev, V ^e   Gibert, R ^f   Kumar, A ^g   Levis, R ^g   Markoff, L ^g   Meyer, H ^h   Morgeaux, S ^f   Tahlan, A ⁱ   Reiner, G ^j   Sabouraud, A ^k   Costa, A ^l   Daviaud, J ^l   Dellepiane, N ^l   Rodriguez Hernandez, C ^l   Wood, David ^l,m,ai   Knezevic, Ivana ^l,m,ai   Briggs, D ⁿ   De Melo, Cardoso ^o   Chader, H ^p   Cliquet, F ^q   Dong, G ^r   Griffiths, E ^s   Ichhpujani, R L ^t   Jivapaisarnpong, T ^u   Mahjoubi, L ^v   Mora, D P ^w   Hoang, Quang Huy ^x   Miranda, N ^y   Rahman, H ^z   Slamet, Lucky S ^aa   Teferi, L ^ab   Wilde, H ^ac   Arisetianingsih, E I P ^aa   Smith, D ^s   Frazatti Gallina, M ^ad   Jadhav, S ^ae   Chamberlin, Catherine ^af   Malerczyk, C ^ag   Sokhey, J ^ah   Kieny, M P ^l   Meslin, F ^l   Hernandez Rodriguez, C ^l   more..

^a INSTITUT PASTEUR   (France)

^b INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^c Oswaldo Cruz Foundation   (Brazil)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^f French Health Products Safety Agency   (France)

^g CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^h PAUL EHRLICH INSTITUT   (Germany)

ⁱ CENTRAL DRUG RESEARCH INSTITUTE   (India)

^j Bulk Manufacturing Germany   (Germany)

^k SANOFI PASTEUR   (France)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m Quality Assurance and Safety of Biologicals   (Switzerland)

ⁿ KANSAS STATE UNIVERSITY   (United States)

^o MINISTÉRIO DA SAÚDE   (Brazil)

^p MINISTÈRE DE LA SANTÉ   (Algeria)

^q Research Laboratory on Rabies and Wild Animal Diseases   (France)

^r NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^s Biologics and Genetic Therapies Directorate   (Canada)

^t GOVERNMENT OF INDIA   (India)

^u MINISTRY OF PUBLIC HEALTH   (Thailand)

^v Ministry of Public Health   (Tunisia)

^w National Regulatory Authority of Cuba   (Cuba)

^x National Center for Quality Control of Biological Products   (Viet Nam)

^y Center for Biologics Evaluation and Research ^*

^z MINISTRY OF HEALTH AND FAMILY WELFARE   (Bangladesh)

^aa NADFC   (Thailand)

^ab Drug Administration and Control Authority   (Ethiopia)

^ac CHULALONGKORN UNIVERSITY   (Thailand)

^ad INSTITUTO BUTANTAN   (Brazil)

^ae Serum Institute of India Ltd   (India)

^af European Directorate for the Quality of Medicines   (France)

^ag Clinical Research and Medical Affairs   (Germany)

^ah WHO Regional Office for South East Asia   (India)

^ai WHO

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CELL DNA; OVALBUMIN; PLASMA PROTEIN; PYROGEN; RABIES VACCINE;

CELL CULTURE; CELL LINE; CERTIFICATION; CHICK EMBRYO; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CULTURE MEDIUM; DATA ANALYSIS; DIPLOIDY; DUCK; EMBRYO CELL; FIBROBLAST; FOWL; HAMSTER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTRACELLULAR FLUID; KIDNEY CELL; LICENSING; MEDICAL INFORMATION; MONITORING; NOMENCLATURE; NONHUMAN; POSTMARKETING SURVEILLANCE; QUALITY CONTROL; RABIES; REVIEW; SAFETY; SAMPLE; SERUM; STANDARD; STORAGE; VACCINE PRODUCTION; VIRUS INFECTIVITY; VIRUS STRAIN; VIRUS TITRATION; ZYGOTE;

EID: 39649118369     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (32)

1. Requirements for rabies vaccine for human use. In: WHO Expert Committee on Biological Standardization. Thirty-first report. Geneva, World Health Organization, 1981, Annex 2 (WHO Technical Report Series, No. 658).
2. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. In: WHO Expert Committee on Biological Standardization. Thirty-ninth report. Geneva, World Health Organization, 1987 (WHO Technical Report Series, No. 760).
3. Requirements for rabies vaccine for human use. In: WHO Expert Committee on Biological Standardization. Forty-third report. Geneva, World Health Organization, 1994, Annex 4 (WHO Technical Report Series, No. 840).
4. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. In: WHO Expert Committee on Biological Standardization. Forty-third report. Geneva, World Health Organization, 1994, Annex 5 (WHO Technical Report Series, No. 840).
5. WHO position paper on rabies vaccines. Weekly Epidemiological Records, No. 14, 2002, 77:109-119.
6. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. The Lancet Infectious Diseases, 2002, 2:327-343.
7. WHO Expert Consultation on Rabies. First report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 931).
8. Meeting report: discussion on WHO requirements for rabies vaccine for human use: potency assay, 20 May 2003. Geneva, World Health Organization, 2003 (http://www.who.int/biologicals/publications/meetings/areas/vaccines/ rabies/en/Rabies%20vaccine%20meeting%20Final%20May%202003.pdf).
9. Meeting Report: Discussion on WHO requirements for rabies vaccine for human use 4-5 May 2004. Geneva, World Health Organization, 2004 (http://www.who.int/biologicals/publications/meetings/areas/vaccines/rabies/en/ Rabies%20vaccine%20meeting%20Final%20May%202004.pdf).
10. Laboratory techniques in rabies. 4th edition. Geneva, World Health Organization, 1996.
11. Hemachuda T et al. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuropathy folowing rabies vaccination. New England Journal of Medicine, 1987, 316, 3:9-74.
12. Parviz S, Luby S, Wilde H. Postexposure treatment of rabies in Pakistan. Clinical Infectious Diseases, 1998, 27:751-755.
13. Parviz et al. Rabies deaths in Pakistan : results of ineffective post-exposure treatment. International Journal of Infectious Diseases, 2004, 8:346-352.
14. Chanthavanich P et al. Antibody response to suckling mouse brain rabies vaccines for post exposure treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 1987, 81:260-263.
15. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. In: WHO Expert Committee on Biological Standardization. Forty-seventh report. Geneva, World Health Organization, 1998, Annex 1 (WHO Technical Report Series, No. 878).
16. Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. Geneva, World Health Organization, 2003 (WHO/BCT/QSD/03.01).
17. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. (Requirements for Biological Substances No. 27, revised 1992). In: WHO Expert Committee on Biological Standardization. Forty-third report. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840).
18. Vaccines and biologicals: Recommendations from the Strategic Advisory Group of Experts. Weekly Epidemiological Record, 2002, 37:306.
19. Good manufacturing practices for pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh Report, Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).
20. Good manufacturing practices for biological products. Geneva, World Health Organizaton, 1992 (WHO Technical Report Series, No. 822):20-30.
21. Laboratory biosafety manual, 3rd edition. Geneva, World Health Organization, 2004.
22. Robertson JS et al. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. Biologicals 1997, 25:403-414.
23. General requirements for the sterility of biological substances (Requirements For Biological Substances No.6, revised 1973). In: WHO Expert Committee on Biological Standardization. Twenty-fifth report, Geneva, World Health Organization, 1973 (Technical Report Series, No. 530) and amended In: WHO Expert Committee on Biological Standardization. Forty-sixth report, Geneva, World Health Organization, 1998 (WHO Technical Report Series, No. 872).
24. Recommendations for the production and control of poliomyelitis vaccine (oral). In: WHO Expert Committee on Biological Standardization. Fiftieth report. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 904).
25. Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-third report. Geneva, World Health Organization, 2004, Annex 4 (WHO Technical Report Series, No. 926).
26. Guidelines for nonclinical evaluation of vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No.927) annex 1.
27. Guidelines for good clinical practices (GCP) for trials on pharmaceutical products. In: WHO Expert Committee on the Use of Essential Drugs, Sixth report. Geneva, World Health Organization, 1995, Annex 3 (WHO Technical Report series, No. 850).
28. Guidelines for clinical evaluation of vaccines: regulatory expectations. In: WHO Expert Committee on Biological Standardization. Fifty-second report. Geneva, World Health Organization, 2004, Annex 1 (WHO Technical Report Series, No. 924).
29. Good Manufacturing Practices: supplementary guidelines for the manufacture of the investigational pharmaceutical products for clinical trials in humans. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: Thirty-Fourth Report, 1996. Annex 7 (WHO Technical Report Series, No. 863).
30. Moore SM et al. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralization assays. Biologicals, 2005, Dec 33(4):269-76.
31. WHO policy statement. The use of opened multi-dose vials of vaccine in subsequent immunization sessions. Geneva, World Health Organization, 2000 (WHO/V&B/00.09).
32. Guidelines for national authorities on quality assurance for biological products. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 822):31-46.